“Secukinumab Treatment in Patients With Spondyloarthritis and Concomitant Demyelinating Disease: Rationale of IL-17 Inhibition and Clinical Outcome”. Archives of Clinical and Medical Case Reports 6, no. 5 (October 5, 2022): 660–668. Accessed September 11, 2026. https://fortunejournals.org/ojs/index.php/acmcr/article/view/22670.